
GHS-R1a, the receptor cloned in 1996 as the target of small synthetic growth hormone secretagogues[1], binds ipamorelin inside its seven-transmembrane bundle, where the ligand is anchored by an ion pair between a protonated amine and Glu124 in transmembrane helix 3. That is the model the available evidence supports, and for ipamorelin it is an extrapolation, not a measurement. No crystal or cryo-EM structure of ipamorelin bound to the receptor has been solved. The structural anchors come from two other directions: site-directed mutagenesis of the receptor against peptide and non-peptide GHS agonists, including MK-0677[2], and cryo-EM structures of GHS-R1a bound to ghrelin and to ibutamoren[3]. Anything specific to ipamorelin’s own contacts is inferred from its position in the GHRP peptide class and from its functional pharmacology[4].
GHS-R1a is a class A GPCR whose pocket sits between the helices
GHS-R1a is a heterotrimeric G-protein-coupled receptor of the pituitary and of the arcuate ventromedial and infundibular hypothalamus in swine and humans, and its distribution supported a neuroendocrine role in pulsatile GH release[1]. When the receptor was cloned, its endogenous ligand was unknown, and the authors proposed that synthetic GHSs mimicked an undiscovered hormone[1]. Ghrelin is that hormone, and its acylation at Ser3 is required for agonist action at GHSR[3].
Antibodies raised against intracellular and extracellular domains confirmed the predicted seven-transmembrane topology in the lipid bilayer[2]. Because the orthosteric pocket of such a receptor lies between the helices rather than in a large extracellular domain, agonist recognition is dominated by small ligand functional groups contacting helix side chains and extracellular loop 1, which is the pattern the mutagenesis work reports[2].
Glu124 in TM3 forms the ion pair shared across GHS chemotypes

Peptide and non-peptide GHS agonists share a binding domain in TM3[2]. The evidence was the E124Q mutation, which removed the counter-ion to the shared basic N+ group of all GHSs and produced a nonfunctional receptor[2]. A complementary ligand change tested the same interface from the other side: converting the amine side chain of MK-0677 to the corresponding alcohol restored function to the E124Q mutant[2]. The rescue argues the pair is direct rather than a folding artefact, because a receptor crippled by misfolding would not recover when only the ligand changes.
For ipamorelin, the shared-amine requirement is where extrapolation starts. The pentapeptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2, so it carries two strong cationic centres at physiological pH, the free N-terminal alpha-amine and the lysine epsilon-amine, while the histidine imidazole is only partly protonated near pH 7.4 and is the weaker candidate for an ion pair[4]. Which of the two amines, if either, occupies the E124 position has not been tested for ipamorelin. The inference that one does rests on ipamorelin acting as a GHRP-receptor agonist, a classification established by antagonist profiling rather than by contact mapping[4].
Contacts outside TM3 separate agonist classes
Mutating residues outside TM3 altered responses in a ligand-class-dependent way: D99N in TM2, M213K and S117A in TM5, H280F in TM6, and C116A in extracellular loop 1[2]. The authors concluded that GHS-R agonism does not require identical disposition of all agonist classes within the binding site, and proposed that the pocket is spatially disposed like the catechol-binding site of the beta2-adrenergic receptor[2].
The practical reading for ipamorelin is that it need not dock like GHRP-6 even though both are peptides. Ipamorelin came from a chemistry series that removed the central Ala-Trp dipeptide of GHRP-1[4], so its side-chain set and backbone geometry differ from the peptides used to define those class contacts. Whether its potency depends on D99, M213, S117, H280 or C116 is unknown, and a class-specific potency loss at one of those positions would be the cheapest way to narrow it down.
The ghrelin and ibutamoren structures define the activated pocket

High-resolution cryo-EM structures of the GHSR-Gi complex bound to ghrelin and to the non-peptide agonist ibutamoren, combined with mutagenesis, resolved the molecular basis of binding for those two agonists[3]. A salt bridge and an aromatic cluster near the agonist-binding pocket emerged as important structural motifs in receptor activation, and the structures showed notable variation in how Gi and GHSR couple[3].
Three limits apply when reading this against ipamorelin. The solved ligands are an acylated peptide hormone and a non-peptide agonist, neither of them a pentapeptide, so ipamorelin’s pose cannot be interpolated from them. The structures also describe activation at motif level (a salt bridge and an aromatic cluster near the pocket), so they show the kind of interaction that holds a GHS agonist, not the identity of each partner that an ipamorelin model would need. The complexes were captured with Gi, while the receptor’s Gq and phospholipase C signalling was characterized in separate transfected-cell experiments[5]. A Gi-coupled structure captures an agonist-bound state; it does not show which G protein carries the pituitary GH signal.
Constitutive activity changes how binding data are read
GHS-R signals without ligand. In transiently transfected COS-7 and HEK293 cells, constitutive activity through Gq and phospholipase C reached about 50% of maximal inositol phosphate accumulation, and constitutive activity was also very high for CRE-driven transcription[5]. The structural basis was traced to an aromatic cluster on the inner face of the extracellular ends of TM VI and VII: activity could be tuned up or down by changing the size and hydrophobicity of the side chain at position VI:16, in the context of an aromatic residue at VII:09 and a large hydrophobic residue at VII:06[5]. The receptor was constitutively internalized and could be trapped at the cell surface by an inverse agonist[5].
The endpoint measured in those assays sits one step upstream of calcium. Gq-coupled receptors activate phospholipase C, which cleaves PIP2 into IP3 and diacylglycerol; IP3 then releases Ca2+ from intracellular stores, and that calcium rise is the proximal trigger for hormone secretion in pituitary somatotrophs. Inositol phosphate accumulation is a proxy for the phospholipase C step, not for the calcium transient itself. For ipamorelin, the reported readouts stop at that proxy and at GH release; intracellular calcium is the expected intermediate, not a measured result.
That baseline affects interpretation of potency comparisons. In a receptor system already half-maximally active, an agonist’s measured effect is a change layered on existing activity, so a small potency difference is harder to attribute to a specific contact than in a silent background. Comparing ipamorelin with GHRP-6 in such a system therefore ranks net signalling rather than occupancy.
What ipamorelin’s own data establish
In primary rat pituitary cells, ipamorelin released GH with potency and efficacy close to GHRP-6 (EC50 1.3 +/- 0.4 nM and Emax 85 +/- 5%, versus 2.2 +/- 0.3 nM and 100%)[4]. GHRP and GHRH antagonist profiling showed that ipamorelin, like GHRP-6, stimulates GH release through a GHRP-like receptor[4]. In pentobarbital-anaesthetised rats and in conscious swine, GH release was again comparable to GHRP-6 in potency and efficacy[4].
The selectivity profile separates ipamorelin from earlier GHRPs. In swine, none of the secretagogues tested altered FSH, LH, PRL or TSH; GHRP-6 and GHRP-2 raised ACTH and cortisol, whereas ipamorelin did not produce ACTH or cortisol levels significantly different from GHRH stimulation, and that held at exposures far above those required for GH release[4]. These are downstream endocrine readouts. They constrain which receptor and cell type is engaged; they do not identify a binding contact, and the data do not resolve the mechanism behind the ACTH difference.
No radioligand-derived affinity for ipamorelin at GHS-R1a is reported. Its numbers are functional — in vitro potency, in vivo GH release, systemic disposition — not a Ki or Kd that would report occupancy of the orthosteric site instead of net output.
Human data sit further from the pocket. A pharmacokinetic-pharmacodynamic model built in healthy volunteers described dose-proportional disposition, a terminal half-life of about 2 hours, and a concentration-GH response relationship, with inter-individual variability larger for pharmacodynamic than for pharmacokinetic parameters[6]. Those are systemic observations; nothing in them localizes ipamorelin on the receptor.
Separating what is measured from what is inferred
| Claim | Direct measurement | Status for ipamorelin |
|---|---|---|
| The agonist pocket lies within the TM bundle | Cryo-EM of ghrelin and ibutamoren; TM2/3/5/6 and ECL1 mutagenesis[2][3] | Strong inference from GHRP-class membership[4] |
| An E124-amine ion pair anchors GHS agonists | E124Q inactivates the receptor; ligand-side charge rescue restores function[2] | Untested; two candidate amines in the sequence[4] |
| An aromatic cluster contributes to activation | Cryo-EM aromatic cluster near the pocket[3]; mutational mapping at TM VI/VII[5] | Contact by D-2-Nal or D-Phe untested |
| Gq/PLC coupling | Constitutive Gq/PLC activity and inositol phosphate accumulation in transfected cells[5] | Consistent with pituitary GH release; not a binding measurement[4] |
| Systemic behaviour | Rat and swine GH release; human PK/PD[4][6] | No structural content |
What would settle ipamorelin’s pose
- E124Q combined with an ipamorelin analogue whose amine is replaced by a neutral group. Recovery of potency by the matched ligand change would reproduce the MK-0677 logic[2].
- A side-chain scan of D-2-Nal and D-Phe against the class-specific positions D99, M213, S117, H280 and C116, looking for a class-dependent loss of potency[2].
- Signalling assays in a receptor background with reduced constitutive activity, so small potency differences are not swamped by basal signalling[5].
- A structure of ipamorelin bound to GHS-R1a, cryo-EM or crystal, the only way to assign its aromatic contacts directly.
Until at least the first is done, statements that ipamorelin "binds Glu124" or "occupies the ibutamoren pocket" are hypotheses with unequal support: the ion pair has the strongest basis, the aromatic contacts the weakest.
Related research: What Is Ipamorelin: Selective GHS-R1a Agonist; Designing Peptide Receptor Assays: Controls and Readouts; Ipamorelin.
Research Use Only Disclaimer. This article is provided for laboratory research and analytical education only. It is not a validated experimental protocol and not medical or veterinary advice, and the materials discussed are not for human or animal use.
References
- A receptor in pituitary and hypothalamus that functions in growth hormone release (Howard AD, 1996; PubMed 8688086)
- Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues (Feighner SD, 1998; PubMed 9440817)
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren (Liu H, 2021; PubMed 34737341)
- Ipamorelin, the first selective growth hormone secretagogue (Raun K, 1998; PubMed 9849822)
- Common structural basis for constitutive activity of the ghrelin receptor family (Holst B, 2004; PubMed 15383539)
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (Gobburu JV, 1999; PubMed 10496658)